KRAS, which can be regarded as a rheostat in cells due to its dependence on the number of active molecules [6], can be utilized as a biomarker to predict the prognosis of PAAD or as a target for tumor therapy [7]. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.